<p>Stoke Therapeutics, Inc.（纳斯达克代码：STOK - 获取免费报告）在周五的期权交易活动中成为异常大型的交易目标。交易者购买了 10,008 份该股票的看涨期权。这比典型的每日 664 份看涨期权的交易量增加了 1,407%。</p>
<p>获取 <strong>Stoke Therapeutics</strong> 的提醒：</p>
<h2>华尔街分析师预测增长</h2>
<p>多家研究公司对 STOK 发表了评论。摩根大通将 Stoke Therapeutics 的目标价格从 15.00 美元上调至 25.00 美元，并在 11 月 3 日的研究报告中给予该公司 “中性” 评级。Weiss Ratings 在周三的研究报告中重申了对 Stoke Therapeutics 股票的 “持有（c-）” 评级。Chardan Capital 在周三的研究报告中将 Stoke Therapeutics 的股票评级提升至 “强力买入”。Wedbush 在 11 月 5 日的研究报告中将 Stoke Therapeutics 的股票目标价格从 22.00 美元上调至 32.00 美元，并给予该股票 “跑赢大盘” 评级。最后，Canaccord Genuity Group 在 11 月 5 日的研究报告中将 Stoke Therapeutics 的股票目标价格从 24.00 美元上调至 28.00 美元，并给予该股票 “买入” 评级。两位投资分析师给予该股票 “强力买入” 评级，六位分析师给予 “买入” 评级，两位分析师给予 “持有” 评级。根据 MarketBeat 的数据，该股票的共识评级为 “买入”，共识目标价格为 31.00 美元。</p>
<p><strong>查看我们对 Stoke Therapeutics 的最新分析</strong></p>
<h2>Stoke Therapeutics 股价上涨 3.0%</h2>
<p>周五中午交易时，STOK 股票上涨 0.83 美元，达到 28.76 美元。该公司的股票交易量为 118,917 股，而其平均交易量为 909,724 股。该公司的市值为 16.4 亿美元，市盈率为 42.93，贝塔值为 1.32。该公司的 50 日移动平均价格为 27.41 美元，200 日移动平均价格为 18.21 美元。Stoke Therapeutics 的 12 个月低点为 5.35 美元，12 个月高点为 38.69 美元。</p>
<p>Stoke Therapeutics（纳斯达克代码：STOK - 获取免费报告）最近在 11 月 4 日发布了季度财报。该公司报告每股收益（EPS）为（0.65 美元），低于分析师的共识预期（0.54 美元）0.11 美元。该季度的收入为 1063 万美元，而共识预期为 606 万美元。Stoke Therapeutics 的股本回报率为 13.28%，净利润率为 19.73%。作为一个整体，股票分析师预计 Stoke Therapeutics 在当前财政年度将发布-2.01 的每股收益。</p>
<h2>Stoke Therapeutics 的内部买卖</h2>
<p>在其他 Stoke Therapeutics 的新闻中，董事 Adrian R. Krainer 在 11 月 14 日的交易中出售了 40,472 股该公司的股票。这些股票以平均价格 26.98 美元出售，总价值为 1,091,934.56 美元。交易完成后，该董事直接持有 364,246 股公司股票，价值约为 9,827,357.08 美元。这代表其持股减少了 10.00%。该出售在向 SEC 的法律文件中披露，可以通过此链接访问。此外，首席法律顾问 Jonathan Allan 在 10 月 3 日的交易中出售了 10,000 股公司的股票。这些股票以平均价格 25.07 美元出售，总交易额为 250,700.00 美元。交易完成后，首席法律顾问直接持有 11,831 股公司的股票，价值为 296,603.17 美元。此次交易使其持股减少了 45.81%。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去 90 天内，内部人士出售了 213,367 股公司股票，价值为 5,110,464 美元。9.50% 的股票由内部人士持有。</p>
<h2>机构资金流入和流出</h2>
<p>几家机构投资者和对冲基金最近买卖了该股票的股份。Corient Private Wealth LLC 在第二季度以 748.9 万美元的估值购买了 Stoke Therapeutics 的新股份。Wellington Management Group LLP 在第三季度将其在 Stoke Therapeutics 的股份增加了 438.2%。Wellington Management Group LLP 现在拥有 737,753 股该公司的股票，价值为 1,733.7 万美元，此前在该期间内又购买了 600,687 股。Polar Capital Holdings Plc 在第三季度将其在 Stoke Therapeutics 的股份增加了 49.8%。Polar Capital Holdings Plc 现在拥有 1,323,470 股该公司的股票，价值为 3,110.2 万美元，此前在该期间内又购买了 439,824 股。Checkpoint Capital L.P.在第一季度将其在 Stoke Therapeutics 的持仓增加了 139.3%。Checkpoint Capital L.P.现在拥有 730,717 股该公司的股票，价值为 485.9 万美元，此前在上个季度又购买了 425,330 股。最后，Erste Asset Management GmbH 在第一季度以约 267 万美元的估值收购了 Stoke Therapeutics 的新股份。</p>
<h2>关于 Stoke Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Stoke Therapeutics, Inc.是一家早期阶段的生物制药公司，开发用于治疗美国严重遗传疾病根本原因的药物。该公司利用其专有的核基因输出靶向增强技术，开发反义寡核苷酸，以选择性地恢复蛋白质水平。</p>
<h2>阅读更多</h2>
<ul>
<li>我们更看好的五只股票比 Stoke Therapeutics 更好</li>
<li>银行股票 - 最值得投资的银行股票</li>
<li>沃尔玛股票在强劲的第三季度后飙升——未来增长更强劲</li>
<li>最佳航空航天股票投资</li>
<li>微软的 AI 超级工厂可能推动股票反弹</li>
<li>10 美元以下的最佳股票</li>
<li>3 只大科技股下滑：背后的原因是什么？</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Stoke Therapeutics 吗？</h2>
<p>在考虑 Stoke Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Stoke Therapeutics 并不在名单上。</p>
<p>虽然 Stoke Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

STOK

<p>Stoke Therapeutics 的期权交易出现显著增长，购买了 10,008 份看涨期权，比平均水平上升了 1,407%。分析师们提高了价格目标，评级范围从 “中性” 到 “强烈买入”。该股票上涨 3.0%，至 28.76 美元，市值为 16.4 亿美元。近期的内部销售和机构投资表明市场对该公司的活跃交易和兴趣</p>

<p>Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) was the target of unusually large options trading activity on Friday. Traders bought 10,008 call options on the stock. This represents an increase of 1,407% compared to the typical daily volume of 664 call options.</p>
<div class="lb-trans"><p>Stoke Therapeutics, Inc.（纳斯达克代码：STOK - 获取免费报告）在周五的期权交易活动中成为异常大型的交易目标。交易者购买了 10,008 份该股票的看涨期权。这比典型的每日 664 份看涨期权的交易量增加了 1,407%。</p>
</div><p>Get <strong>Stoke Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Stoke Therapeutics</strong> 的提醒：</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of research firms have commented on STOK. JPMorgan Chase &amp; Co. upped their price target on Stoke Therapeutics from $15.00 to $25.00 and gave the company a &#34;neutral&#34; rating in a research report on Monday, November 3rd. Weiss Ratings reaffirmed a &#34;hold (c-)&#34; rating on shares of Stoke Therapeutics in a research note on Wednesday. Chardan Capital raised shares of Stoke Therapeutics to a &#34;strong-buy&#34; rating in a research report on Wednesday. Wedbush boosted their price target on shares of Stoke Therapeutics from $22.00 to $32.00 and gave the stock an &#34;outperform&#34; rating in a research report on Wednesday, November 5th. Finally, Canaccord Genuity Group increased their price objective on shares of Stoke Therapeutics from $24.00 to $28.00 and gave the stock a &#34;buy&#34; rating in a research report on Wednesday, November 5th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of &#34;Buy&#34; and a consensus target price of $31.00.</p>
<div class="lb-trans"><p>多家研究公司对 STOK 发表了评论。摩根大通将 Stoke Therapeutics 的目标价格从 15.00 美元上调至 25.00 美元，并在 11 月 3 日的研究报告中给予该公司 “中性” 评级。Weiss Ratings 在周三的研究报告中重申了对 Stoke Therapeutics 股票的 “持有（c-）” 评级。Chardan Capital 在周三的研究报告中将 Stoke Therapeutics 的股票评级提升至 “强力买入”。Wedbush 在 11 月 5 日的研究报告中将 Stoke Therapeutics 的股票目标价格从 22.00 美元上调至 32.00 美元，并给予该股票 “跑赢大盘” 评级。最后，Canaccord Genuity Group 在 11 月 5 日的研究报告中将 Stoke Therapeutics 的股票目标价格从 24.00 美元上调至 28.00 美元，并给予该股票 “买入” 评级。两位投资分析师给予该股票 “强力买入” 评级，六位分析师给予 “买入” 评级，两位分析师给予 “持有” 评级。根据 MarketBeat 的数据，该股票的共识评级为 “买入”，共识目标价格为 31.00 美元。</p>
</div><p><strong>View Our Latest Analysis on Stoke Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Stoke Therapeutics 的最新分析</strong></p>
</div><h2>Stoke Therapeutics Trading Up 3.0%</h2>
<div class="lb-trans"><h2>Stoke Therapeutics 股价上涨 3.0%</h2>
</div><p>STOK stock traded up $0.83 during mid-day trading on Friday, reaching $28.76. The company's stock had a trading volume of 118,917 shares, compared to its average volume of 909,724. The company has a market cap of $1.64 billion, a price-to-earnings ratio of 42.93 and a beta of 1.32. The business's 50 day moving average price is $27.41 and its 200 day moving average price is $18.21. Stoke Therapeutics has a 12 month low of $5.35 and a 12 month high of $38.69.</p>
<div class="lb-trans"><p>周五中午交易时，STOK 股票上涨 0.83 美元，达到 28.76 美元。该公司的股票交易量为 118,917 股，而其平均交易量为 909,724 股。该公司的市值为 16.4 亿美元，市盈率为 42.93，贝塔值为 1.32。该公司的 50 日移动平均价格为 27.41 美元，200 日移动平均价格为 18.21 美元。Stoke Therapeutics 的 12 个月低点为 5.35 美元，12 个月高点为 38.69 美元。</p>
</div><p>Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.54) by ($0.11). The business had revenue of $10.63 million for the quarter, compared to the consensus estimate of $6.06 million. Stoke Therapeutics had a return on equity of 13.28% and a net margin of 19.73%. As a group, equities analysts expect that Stoke Therapeutics will post -2.01 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Stoke Therapeutics（纳斯达克代码：STOK - 获取免费报告）最近在 11 月 4 日发布了季度财报。该公司报告每股收益（EPS）为（0.65 美元），低于分析师的共识预期（0.54 美元）0.11 美元。该季度的收入为 1063 万美元，而共识预期为 606 万美元。Stoke Therapeutics 的股本回报率为 13.28%，净利润率为 19.73%。作为一个整体，股票分析师预计 Stoke Therapeutics 在当前财政年度将发布-2.01 的每股收益。</p>
</div><h2>Insider Buying and Selling at Stoke Therapeutics</h2>
<div class="lb-trans"><h2>Stoke Therapeutics 的内部买卖</h2>
</div><p>In other Stoke Therapeutics news, Director Adrian R. Krainer sold 40,472 shares of the company's stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $26.98, for a total value of $1,091,934.56. Following the completion of the transaction, the director directly owned 364,246 shares in the company, valued at approximately $9,827,357.08. This represents a 10.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, General Counsel Jonathan Allan sold 10,000 shares of the firm's stock in a transaction on Friday, October 3rd. The shares were sold at an average price of $25.07, for a total transaction of $250,700.00. Following the transaction, the general counsel directly owned 11,831 shares of the company's stock, valued at $296,603.17. The trade was a 45.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 213,367 shares of company stock valued at $5,110,464. 9.50% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在其他 Stoke Therapeutics 的新闻中，董事 Adrian R. Krainer 在 11 月 14 日的交易中出售了 40,472 股该公司的股票。这些股票以平均价格 26.98 美元出售，总价值为 1,091,934.56 美元。交易完成后，该董事直接持有 364,246 股公司股票，价值约为 9,827,357.08 美元。这代表其持股减少了 10.00%。该出售在向 SEC 的法律文件中披露，可以通过此链接访问。此外，首席法律顾问 Jonathan Allan 在 10 月 3 日的交易中出售了 10,000 股公司的股票。这些股票以平均价格 25.07 美元出售，总交易额为 250,700.00 美元。交易完成后，首席法律顾问直接持有 11,831 股公司的股票，价值为 296,603.17 美元。此次交易使其持股减少了 45.81%。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去 90 天内，内部人士出售了 213,367 股公司股票，价值为 5,110,464 美元。9.50% 的股票由内部人士持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Several institutional investors and hedge funds have recently bought and sold shares of the stock. Corient Private Wealth LLC bought a new stake in Stoke Therapeutics in the second quarter valued at $7,489,000. Wellington Management Group LLP grew its stake in shares of Stoke Therapeutics by 438.2% in the 3rd quarter. Wellington Management Group LLP now owns 737,753 shares of the company's stock valued at $17,337,000 after buying an additional 600,687 shares during the period. Polar Capital Holdings Plc grew its stake in shares of Stoke Therapeutics by 49.8% in the 3rd quarter. Polar Capital Holdings Plc now owns 1,323,470 shares of the company's stock valued at $31,102,000 after buying an additional 439,824 shares during the period. Checkpoint Capital L.P. increased its position in Stoke Therapeutics by 139.3% in the 1st quarter. Checkpoint Capital L.P. now owns 730,717 shares of the company's stock valued at $4,859,000 after buying an additional 425,330 shares in the last quarter. Finally, Erste Asset Management GmbH acquired a new position in Stoke Therapeutics during the 1st quarter worth approximately $2,670,000.</p>
<div class="lb-trans"><p>几家机构投资者和对冲基金最近买卖了该股票的股份。Corient Private Wealth LLC 在第二季度以 748.9 万美元的估值购买了 Stoke Therapeutics 的新股份。Wellington Management Group LLP 在第三季度将其在 Stoke Therapeutics 的股份增加了 438.2%。Wellington Management Group LLP 现在拥有 737,753 股该公司的股票，价值为 1,733.7 万美元，此前在该期间内又购买了 600,687 股。Polar Capital Holdings Plc 在第三季度将其在 Stoke Therapeutics 的股份增加了 49.8%。Polar Capital Holdings Plc 现在拥有 1,323,470 股该公司的股票，价值为 3,110.2 万美元，此前在该期间内又购买了 439,824 股。Checkpoint Capital L.P.在第一季度将其在 Stoke Therapeutics 的持仓增加了 139.3%。Checkpoint Capital L.P.现在拥有 730,717 股该公司的股票，价值为 485.9 万美元，此前在上个季度又购买了 425,330 股。最后，Erste Asset Management GmbH 在第一季度以约 267 万美元的估值收购了 Stoke Therapeutics 的新股份。</p>
</div><h2>About Stoke Therapeutics</h2>
<div class="lb-trans"><h2>关于 Stoke Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.</p>
<div class="lb-trans"><p>Stoke Therapeutics, Inc.是一家早期阶段的生物制药公司，开发用于治疗美国严重遗传疾病根本原因的药物。该公司利用其专有的核基因输出靶向增强技术，开发反义寡核苷酸，以选择性地恢复蛋白质水平。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>阅读更多</h2>
</div><ul>
<li>Five stocks we like better than Stoke Therapeutics</li>
<li>Bank Stocks - Best Bank Stocks to Invest In</li>
<li>Walmart Stock Surges After a Solid Q3—Stronger Growth Ahead</li>
<li>Best Aerospace Stocks Investing</li>
<li>Microsoft’s AI Superfactory Could Power a Stock Rally</li>
<li>Best Stocks Under $10.00</li>
<li>3 Big Tech Stocks Sliding: What’s Behind the Drop?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Stoke Therapeutics 更好</li>
<li>银行股票 - 最值得投资的银行股票</li>
<li>沃尔玛股票在强劲的第三季度后飙升——未来增长更强劲</li>
<li>最佳航空航天股票投资</li>
<li>微软的 AI 超级工厂可能推动股票反弹</li>
<li>10 美元以下的最佳股票</li>
<li>3 只大科技股下滑：背后的原因是什么？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Stoke Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Stoke Therapeutics 吗？</h2>
</div><p>Before you consider Stoke Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Stoke Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stoke Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Stoke Therapeutics 并不在名单上。</p>
</div><p>While Stoke Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Stoke Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Stoke Therapeutics 成为异常高期权交易的目标（NASDAQ:STOK）